Showing 4251-4260 of 5328 results for "".
- First EB Patient Enrolled in PK Study of Diacerein 1% Ointmenthttps://practicaldermatology.com/news/first-eb-patient-enrolled-in-pk-study-of-diacerein-1-ointment/2457716/The first patient has been enrolled in a new Phase 1 study evaluating the pharmacokinetics (PK) and safety of Castle Creek Pharmaceuticals’ diacerein 1% ointment (CCP-020) under maximum use conditions in patients with epidermolysis bullosa (EB)
- FDA-Approved Label Update: Cosentyx Inhibits Progression of Joint Structural Damage in PsAhttps://practicaldermatology.com/news/fda-approved-label-update-cosentyx-inhibits-progression-of-joint-structural-damage-in-psa/2457718/The US FDA has approved a label update for Cosentyx® (secukinumab) from Novartis, including data that show the treatment significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA). The data will be a
- Alana Sine is New CFO at Merz North Americahttps://practicaldermatology.com/news/alan-sine-is-new-cfo-at-merz-north-america/2457719/Merz North America has appointed Alana Sine as Chief Financial Officer (CFO), Merz North America. Ms. Sine has served as interim CFO since March 2018. Ms. Sine will lead the finance function for North America, overseeing finan
- Michael Mazen Jafar is New Chief Marketing Officer at Evolushttps://practicaldermatology.com/news/michael-mazen-jafar-is-new-chief-marketing-officer-at-elovus/2457722/Evolus, Inc. has expanded its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juve
- Valeant: FDA Issues Complete Response Letter for Duobriihttps://practicaldermatology.com/news/valeant-fda-issues-complete-response-letter-for-duobrii/2457723/Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. has received a Complete Response Letter (CRL) from the US FDA
- New Data from DermTech Presented at International Investigational Dermatology Meetinghttps://practicaldermatology.com/news/new-data-from-dermtech-presented-at-international-investigational-dermatology-meeting/2457724/DermTech, Inc., has announced the publication of two clinical study abstracts at the 2018 International Investigational Dermatology meeting
- eRelevance Launches Suite of Services to Support Lead Conversionhttps://practicaldermatology.com/news/erelevance-launches-suite-of-services-to-support-lead-conversion/2457726/eRelevance Corporation has launched a suite of tech-powered services to help
- Restoration Robotics Launches Continuing Education Master Class for ARTAS Systemhttps://practicaldermatology.com/news/restoration-robotics-launches-continuing-education-master-class-for-artas-system/2457729/Restoration Robotics, Inc. is launching a continuing education Master Class Series for its ARTAS® Robotic Hair Restoration System to train physicians on best practices and the most up-to-date techniques for the technology. The Master Class Series will enable users to provide exceptional
- ThermiVa: First-ever Data Show Vaginal Regenerationhttps://practicaldermatology.com/news/thermiva-first-ever-data-show-vaginal-regeneration/2457730/Thermi’s ThermiVa® device has been shown to deliver significant improvements in common vaginal disorders and improve sexual satisfaction, according to a study published in Dermatologic Surgery. Since it was cleared by the FDA in 2013, ThermiVa has been used
- Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumabhttps://practicaldermatology.com/news/opdivo-data-superior-recurrence-free-survival-versus-ipilimumab/2457734/Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) in patients with stage IIIB/C or stage IV melanoma who are at high ri